secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001193125-24-138211
Event type: debt
Sentiment:  neutral
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm closes $148M debt exchange for new 6% notes due 2029 and warrants, plus $100M credit facility
--------------------------------------------------------------------------------

- Exchanged ~$148M of 3.00% convertible notes due 2025 for $111M of new 6.00% secured convertible notes due 2029.
- Issued warrants to purchase up to ~46M shares of common stock as part of the exchange.
- Entered into a $100M senior secured credit facility, with proceeds used partly to repay HCR facility and for general purposes.
- The exchange extends debt maturity from 2025 to 2029, improving near-term liquidity but increasing interest cost and adding dilution potential.
- New notes are secured and carry a 6% coupon versus the 3% on the exchanged notes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000119312524138211/0001193125-24-138211-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000119312524138211/d808759d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-138211

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer